Rexam gains Mexican packaging plant
This article was originally published in The Rose Sheet
Executive Summary
UK-based firm with vision "to be the leading global consumer packaging company" - it currently is No. 2 - assumes ownership of plastic packaging injection and extrusion blow-molded manufacturing plant in Tlalnepantla, Mexico City with purchase of remaining 50% interest in joint venture between it and Pavisa Industries. Consistent with the company's goal of building its presence in emerging markets, "Rexam will be utilizing the plant to exploit growth for plastic packaging across the healthcare, closures and personal-care industries in the Mexico and Latin American markets," according to Feb. 24 announcement. The Mexico City facility has more than 300 employees, Rexam says, and produces plastic for the pharmaceutical and diagnostic industries as well as for firms needing cases for lipsticks, mascaras and compacts and dispensing solutions for perfumes, lotions and foams. Firm reported Feb. 19 that its fiscal 2008 full-year sales totaled $6.54 bil., up 28% from 2007 including the benefit of recent acquisitions and foreign currency exchange
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.